<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061863</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG BR18-16</org_study_id>
    <nct_id>NCT04061863</nct_id>
  </id_info>
  <brief_title>Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer</brief_title>
  <acronym>KORNELIA</acronym>
  <official_title>A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Cancer Study Group (KCSG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono pharmaceutical Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in&#xD;
      favor of the immune system. Chemotherapy can result in tumor cell death with a resultant&#xD;
      increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining&#xD;
      immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>ER+/HER2- BC cohort: 45 pts ER-/HER2- (Triple negative) BC cohort: 45 pts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months progression-free survival (PFS) rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate by RECIST criteria v 1.1</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years (upto 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Rate of each Toxicity by CTCAE 4.0</measure>
    <time_frame>2 years (upto 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate by RECIST criteria v 1.1 (and iRECIST)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ER+/HER2- breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will be treated with a combination of eribulin and nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER-/HER2- breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will be treated with a combination of eribulin and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks</description>
    <arm_group_label>ER+/HER2- breast cancer</arm_group_label>
    <arm_group_label>ER-/HER2- breast cancer</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Age 20 years or older&#xD;
&#xD;
          -  ECOG performance status(PS) 0 or 1&#xD;
&#xD;
          -  Histologically confirmed stage IV or recurrent breast cancer&#xD;
&#xD;
          -  HER2 negative disease: not eligible for anti-HER2 therapy&#xD;
&#xD;
             * HER2 negative [IHC 0, 1+ or IHC 2+ with corresponding ISH non-amplified or ratio&#xD;
             less than 2.0 or ISH non-amplified ratio less than 2.0] as per ASCO-CAP HER2 guideline&#xD;
             recommendations 2013 (ASCO-CAP)&#xD;
&#xD;
          -  Patients previously treated with anthracycline and/or taxane unless contraindicated;&#xD;
             Patients who received anthracycline and/or taxane based chemotherapy in either the&#xD;
             neoadjuvant, adjuvant or metastatic setting and experienced disease progression on or&#xD;
             after taxane-based chemotherapy in the metastatic setting&#xD;
&#xD;
          -  No more than 3 prior lines of cytotoxic chemotherapy for metastatic disease; patients&#xD;
             who experienced disease recurrence within 1 year after completion of (neo)adjuvant&#xD;
             anthracycline and taxane-based chemotherapy will be counted as 1 prior line of&#xD;
             treatment.; hormonal therapy will not be counted as a prior line of treatment&#xD;
&#xD;
          -  Measurable disease according to RECIST v 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with eribulin mesylate or any anti-PD-1, PD-L1, or PD-L2&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive&#xD;
             drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Known central nervous system (CNS) disease, except for those subjects with treated&#xD;
             brain metastasis who are stable for at least 1 month, having no evidence of&#xD;
             progression or hemorrhage after treatment and no ongoing requirement for&#xD;
             corticosteroids, as ascertained by clinical examination and brain imaging (magnetic&#xD;
             resonance imaging [MRI] or computed tomography [CT]) during the screening period&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Known active hepatitis B or hepatitis C (eg, HCV RNA detected)&#xD;
&#xD;
          -  Any other malignancy that required treatment or has shown evidence of recurrence&#xD;
             (except for nonmelanoma skin cancer, or histologically confirmed complete excision of&#xD;
             carcinoma in situ) during the 3 years prior to enrollment in this study&#xD;
&#xD;
          -  History of significant cardiovascular disease&#xD;
&#xD;
          -  Hypersensitivity to the active substance or any other excipients of the eribulin&#xD;
             mesylate drug product, or to nivolumab&#xD;
&#xD;
          -  Scheduled for major surgery during the study&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment. The use of physiologic doses of corticosteroids may be allowed&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis that required steroids or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has a history of interstitial lung disease&#xD;
&#xD;
          -  Has received a live-virus vaccination within 30 days of planned start of study&#xD;
             therapy. Seasonal flu vaccines that do not contain live virus are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JEEHYUN KIM, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.kcsg.org/en/index.do</url>
    <description>Korea Cancer Study Group</description>
  </link>
  <link>
    <url>https://www.snubh.org/index.do</url>
    <description>Seoul National University Bundang Hospital</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>September 5, 2021</last_update_submitted>
  <last_update_submitted_qc>September 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>eribulin</keyword>
  <keyword>nivolumab</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>immune checkpoint inhibitor</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

